담낭암 환자에서 Gemcitabine을 기본으로 한 보조 항암화학요법의 경험

Purpose: Patients with gallbladder cancer tend to have advanced, unresectable tumor at the time of presentation and they face a dismal prognosis in the absence of a standard chemotherapy regimen. This study was performed to evaluate the outcomes of patients with gallbladder cancer and who underwent...

Full description

Saved in:
Bibliographic Details
Published inAnnals of surgical treatment and research Vol. 75; no. 4; pp. 255 - 261
Main Authors 이승원(Seung Won Lee), 김형철(Hyung Chul Kim), 주종우(Chong Woo Chu), 정준철(Jun Chul Chung), 정귀애(Gui Ae Chung)
Format Journal Article
LanguageKorean
Published 대한외과학회 01.10.2008
Subjects
Online AccessGet full text
ISSN2288-6575
2288-6796

Cover

Loading…
More Information
Summary:Purpose: Patients with gallbladder cancer tend to have advanced, unresectable tumor at the time of presentation and they face a dismal prognosis in the absence of a standard chemotherapy regimen. This study was performed to evaluate the outcomes of patients with gallbladder cancer and who underwent postoperative gemcitabine-based chemotherapy. Methods: From March of 2001 to February of 2008, a total of 27 patients underwent operation for gallbladder cancer. They underwent two types of gemcitabine-based chemotherapy. One type of regimen was the combined administration of gemcitabine 1,000 mg/m2 and 5-fluorouracil 200 mg/m2. The other one was combined administration of gemcitabine 1,000 mg/m2 and cisplatin 70 mg/m2. Results: Among the 27 patients, 15 patients were treated with gemcitabine-based chemotherapy and 12 patients were treated with many kinds of the best supportive care without chemotherapy. The median survival was 29.1±2.7 months and 15.7±2.8 months, respectively. The median survival and disease free survival for the gemcitabine based chemotherapy group who received curative resection was 31.6±2.5 and 15.7±3.2 months, respectively. The median survival and disease free survival for the patients without chemotherapy after curative resection was 16.3±2.9 and 15.7±3.2 months, respectively. Conclusion: Patients with gallbladder cancer and who received adjuvant gemcitabine-based chemotherapy had a relatively favorable prognosis. Especially, gemcitabine-based combination chemotherapy could be effective and acceptable for the treatment of gallbladder cancer patients who have undergone curative resection. (J Korean Surg Soc 2008;75:255-261) KCI Citation Count: 2
Bibliography:G704-000991.2008.75.4.010
ISSN:2288-6575
2288-6796